Cambiar Investors LLC cut its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 11.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 473,641 shares of the company’s stock after selling 60,432 shares during the quarter. Cambiar Investors LLC’s holdings in Eli Lilly and were worth $40,515,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Vanguard Group Inc. boosted its position in Eli Lilly and by 2.3% during the second quarter. Vanguard Group Inc. now owns 70,207,891 shares of the company’s stock worth $5,778,109,000 after acquiring an additional 1,610,885 shares during the last quarter. BlackRock Inc. boosted its position in Eli Lilly and by 2.1% during the second quarter. BlackRock Inc. now owns 63,583,747 shares of the company’s stock worth $5,232,942,000 after acquiring an additional 1,323,259 shares during the last quarter. Janus Henderson Group PLC boosted its position in Eli Lilly and by 7,093.5% during the second quarter. Janus Henderson Group PLC now owns 9,353,275 shares of the company’s stock worth $769,774,000 after acquiring an additional 9,223,251 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Eli Lilly and by 8.4% in the 1st quarter. Geode Capital Management LLC now owns 9,103,975 shares of the company’s stock valued at $764,597,000 after purchasing an additional 708,597 shares during the last quarter. Finally, Janus Capital Management LLC boosted its holdings in Eli Lilly and by 2.8% in the 1st quarter. Janus Capital Management LLC now owns 8,723,692 shares of the company’s stock valued at $733,731,000 after purchasing an additional 237,619 shares during the last quarter. Hedge funds and other institutional investors own 76.42% of the company’s stock.

Several equities analysts have weighed in on the stock. Credit Suisse Group reiterated a “hold” rating on shares of Eli Lilly and in a report on Wednesday. BMO Capital Markets set a $73.00 target price on shares of Eli Lilly and and gave the company a “sell” rating in a report on Tuesday, December 12th. Morgan Stanley boosted their target price on shares of Eli Lilly and from $86.00 to $90.00 and gave the company an “equal weight” rating in a report on Tuesday, November 21st. Zacks Investment Research lowered shares of Eli Lilly and from a “buy” rating to a “hold” rating in a report on Monday, October 30th. Finally, Berenberg Bank reiterated a “buy” rating and issued a $98.00 target price on shares of Eli Lilly and in a report on Thursday, October 26th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $90.25.

In other news, major shareholder Lilly Endowment Inc sold 205,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $86.81, for a total value of $17,796,050.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Susan Mahony sold 36,585 shares of the business’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $86.18, for a total transaction of $3,152,895.30. Following the completion of the sale, the senior vice president now directly owns 54,885 shares in the company, valued at $4,729,989.30. The disclosure for this sale can be found here. Insiders sold a total of 651,088 shares of company stock worth $56,439,586 over the last three months. Insiders own 0.20% of the company’s stock.

Shares of Eli Lilly and Company (NYSE:LLY) opened at $86.54 on Friday. The stock has a market cap of $95,321.79, a P/E ratio of 21.17, a PEG ratio of 1.76 and a beta of 0.35. Eli Lilly and Company has a 52 week low of $71.76 and a 52 week high of $89.09. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.03 by $0.02. The business had revenue of $5.66 billion for the quarter, compared to the consensus estimate of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The business’s revenue was up 9.0% on a year-over-year basis. During the same period in the previous year, the firm earned $0.88 EPS. sell-side analysts anticipate that Eli Lilly and Company will post 4.22 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Stockholders of record on Thursday, February 15th will be paid a $0.5625 dividend. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.60%. This is an increase from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend is Wednesday, February 14th. Eli Lilly and’s payout ratio is 98.58%.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/12/17/cambiar-investors-llc-sells-60432-shares-of-eli-lilly-and-company-lly.html.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Stock Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related stocks with our FREE daily email newsletter.